{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-24-011072","form_type":"8-K","ticker":"NDRA","cik":"0001681682","company_name":"ENDRA Life Sciences Inc.","filed_at":"2024-08-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.096170+00:00","generated_at":"2026-05-31T07:51:27.380006+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"medium","headline":"ENDRA Life Sciences appoints new CEO, raises $8M, reduces annual OpEx by $3.1M","bullets":["New acting CEO Alexander Tokman appointed; CFO Richard Jacroux and Regulatory head Ziad Rouag join.","Gross proceeds of $8.0M from public offering of common stock and warrants.","Annualized operating expenses reduced by $3.1M (26%) vs prior year; Q2 OpEx $2.2M.","Cash and cash equivalents $6.4M at June 30, 2024.","Advanced FDA regulatory process; initiated new pilot trials at two North American sites."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-24-011072","json":"https://secwatch.observer/filing/0001654954-24-011072.json","markdown":"https://secwatch.observer/filing/0001654954-24-011072.md","text":"https://secwatch.observer/filing/0001654954-24-011072.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681682/000165495424011072/0001654954-24-011072-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681682/000165495424011072/endra_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T07:51:27.380006+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}